Earnings Call · Q1 FY2025·2026-03-25

Q1 25EPS +100.00%*·Rev n/aQ4 24EPS -39.73%·Rev n/aQ3 24EPS -5.00%·Rev n/aQ2 24EPS -2.56%·Rev n/a⚠ consensus missing

KalVista Pharmaceuticals, Inc. KALV

Ryan Baker — Head of Investor Relations

Benjamin Palleiko — Chief Executive Officer

Paul Audhya — Chief Medical Officer

Nicole Sweeny — Head of U.S. Commercial

Brian Piekos — Chief Financial Officer

+4.1%1d on move date+3.6% vs SPY3d+17.4%5d+22.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more KALV calls or request research access.

More KALV calls Browse calls Request research access